Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575132 | 0.95 | FTO (0.34) | LMNAMAPTKDM4EGLAGAA | |
| SCHEMBL306238 | 0.82 | GSTP1 (0.36) | LMNAMAPTKDM4EGLAGAA | |
| SCHEMBL6263093 | 0.82 | ALDH1A1 (0.52) | LMNAMAPTKDM4EGLAGAA | |
| SCHEMBL4236674 | 0.78 | LMNA (0.32) | LMNAMAPTKDM4EGLAGAA | |
| SCHEMBL3776396 | 0.73 | — | — | |
| SCHEMBL315867 | 0.73 | FTO (0.45) | MAPTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL1024927 | 0.69 | MAPT (0.66) | LMNAMAPTGAAMEN1ALDH1A1 | |
| SCHEMBL29349570 | 0.69 | MAPT (0.66) | LMNAMAPTGAAMEN1ALDH1A1 | |
| SCHEMBL17674787 | 0.69 | LMNA (0.35) | LMNAMAPTKDM4EGLAGAA | |
| SCHEMBL20419954 | 0.67 | ALDH1A1 (0.49) | LMNAMAPTKDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272666-B1 | A FUNCTIONAL ASSAY OF HIGH-DENSITY LIPOPROTEIN | UNIV CALIFORNIA (US) | 2005-10-12 | — | — | EP | claimed |
| WO-2021025533-A1 | COMPOSITION COMPRISING SKELETAL MUSCLE STEM CELL-DERIVED EXOSOME AS ACTIVE INGREDIENT FOR IMPROVING SKIN CONDITION | 건국대학교 산학협력단 | 2021-02-11 | — | — | WO | disclosed |
| US-9814707-B2 | Cancer stem cell proliferation inhibitor and intracellular active oxygen accumulation inducer | KEIO UNIVERSITY (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20170105984-A1 | CANCER STEM CELL PROLIFERATION INHIBITOR AND INTRACELLULAR ACTIVE OXYGEN ACCUMULATION INDUCER | KEIO UNIVERSITY (JP) | 2017-04-20 | — | — | US | disclosed |
| EP-3120849-A1 | CANCER STEM CELL PROLIFERATION INHIBITOR AND INTRACELLULAR ACTIVE OXYGEN ACCUMULATION INDUCER | Keio University (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-8703200-B2 | Inhibition of neovascularization by cerium oxide nanoparticles | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120093931-A9 | Inhibition of Neovascularization by Cerium Oxide Nanoparticles | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2012-04-19 | — | — | US | disclosed |
| US-8088419-B2 | Sulfur-containing proanthocyanidin oligomer composition and production method thereof | AMINO UP CHEMICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110111007-A1 | INHIBITION OF RETINAL CELL DEGENERATION OR NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-05-12 | — | — | US | disclosed |
| US-7939116-B2 | Sulfur-containing proanthocyanidin oligomer composition and production method thereof | AMINO UP CHEMICAL CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| EP-1524270-B1 | SULFUR-CONTAINING PROANTHOCYANIDIN OLIGOMER COMPOSITION AND PROCESS FOR PRODUCING THE SAME | AMINO UP CHEMICAL CO LTD (JP) | 2009-08-26 | — | — | EP | disclosed |
| EP-1768660-A4 | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | ATHEROGENICS INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2007412-A2 | THERAPEUTIC TARGET MOLECULES FOR THE DEVELOPMENT OF NOVEL MEDICAMENTS FOR DEGENERATIVE DISEASES | Neuroprofile GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007121721-A2 | THERAPEUTIC TARGET MOLECULES FOR THE DEVELOPMENT OF NOVEL MEDICAMENTS FOR DEGENERATIVE DISEASES | NEUROPROFILE GMBH (DE) | 2007-11-01 | — | — | WO | disclosed |
| EP-1768660-A2 | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | Atherogenics, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015022-B2 | Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities | UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060058268-A1 | Compounds and methods for treating diabetic vascular diseases | CRABTREE ACQUISITION CO, LLC | 2006-03-16 | — | — | US | disclosed |
| WO-2006007508-A2 | COMPOUNDS AND METHODS FOR TREATING DIABETIC VASCULAR DISEASES | ATHEROGENICS, INC. (US) | 2006-01-19 | — | — | WO | disclosed |
| US-20050261198-A1 | Sulfur-containing proanthocyanidin oligomer compositon and process for producing the same | Amino Up Co., Ltd. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1524270-A1 | SULFUR-CONTAINING PROANTHOCYANIDIN OLIGOMER COMPOSITION AND PROCESS FOR PRODUCING THE SAME | AMINO UP CHEMICAL CO. LTD. (JP) | 2005-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261198-A1 | Sulfur-containing proanthocyanidin oligomer compositon and process for producing the same | CTH, CBS, PYGB | LMNA 2513/4885MAPT 140/4885KDM4E 4715/4885 |
| US-20170105984-A1 | CANCER STEM CELL PROLIFERATION INHIBITOR AND INTRACELLULAR ACTIVE OXYGEN ACCUMULATION INDUCER | MKI67, MYC, MCL1 | LMNA 4135/4885MAPT 2894/4885KDM4E 2340/4885 |
| US-20060058268-A1 | Compounds and methods for treating diabetic vascular diseases | REN, SLC5A2, SLC5A1 | LMNA 1764/4885MAPT 2120/4885KDM4E 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.